,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'enhertu']
 given the overall survival benefit this is practice-changing and will potentially open up treatment for a whole new group of patients, says our dr. jennifer litton of enhertu for patients with advanced breast cancer. #asco22 #endcancer 
Driven by our mission to #EndCancer, MD Anderson is a leader in cancer care, research, education and training, and prevention. Appointments: 1-877-632-6789